Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Invested Capital (2016 - 2025)

Historic Invested Capital for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $2.7 billion.

  • Dexcom's Invested Capital rose 3060.02% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 billion, marking a year-over-year increase of 3060.02%. This contributed to the annual value of $2.7 billion for FY2025, which is 3060.02% up from last year.
  • As of Q4 2025, Dexcom's Invested Capital stood at $2.7 billion, which was up 3060.02% from $2.7 billion recorded in Q3 2025.
  • In the past 5 years, Dexcom's Invested Capital registered a high of $2.7 billion during Q4 2025, and its lowest value of $1.6 billion during Q1 2021.
  • Moreover, its 5-year median value for Invested Capital was $2.2 billion (2022), whereas its average is $2.2 billion.
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 7600.86% in 2021, then plummeted by 1273.87% in 2024.
  • Dexcom's Invested Capital (Quarter) stood at $2.0 billion in 2021, then increased by 4.39% to $2.1 billion in 2022, then dropped by 2.96% to $2.1 billion in 2023, then rose by 1.64% to $2.1 billion in 2024, then soared by 30.6% to $2.7 billion in 2025.
  • Its Invested Capital was $2.7 billion in Q4 2025, compared to $2.7 billion in Q3 2025 and $2.6 billion in Q2 2025.